SCHEMBL13622970

SCHEMBL13622970

CC(C)(C)OC(=O)Nc1cccc(NC(=O)c2cccc(Nc3nc(Cl)ncc3Cl)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.51
MET P08581 1/20 0.47
STK17B O94768 1/20 0.46
STK17A Q9UEE5 1/20 0.46
NAMPT P43490 1/20 0.45
BRD4 O60885 1/20 0.45
KAT6A Q92794 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
KCNQ3 O43525 3/20 0.43
KCNQ2 O43526 3/20 0.43
KCNQ5 Q9NR82 3/20 0.43
KCNE1 P15382 2/20 0.43
KCNQ1 P51787 2/20 0.43
CDK1 P06493 1/20 0.43
EGFR P00533 4/20 0.42
SRC P12931 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180112 0.93 SYK (0.57) SYKMETSTK17BSTK17ABRD4
SCHEMBL13623006 0.88 MET (0.47) SYKMETSTK17BSTK17ANAMPT
SCHEMBL29538059 0.86 SYK (0.51) SYKNAMPTBRD4KAT6ACDK1
SCHEMBL1026707 0.84 MEN1 (0.49) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL13623023 0.84 MET (0.49) SYKMETSTK17BSTK17ABRD4
SCHEMBL13623118 0.84 AURKA (0.50) SYKMETSTK17BSTK17ABRD4
SCHEMBL13623131 0.83 SYK (0.50) SYKMETSTK17BSTK17ABRD4
SCHEMBL9923768 0.83 SYK (0.56) SYKMETSTK17BSTK17ABRD4
SCHEMBL30306552 0.83 SYK (0.56) SYKMETSTK17BSTK17ABRD4
SCHEMBL13623014 0.83 BTK (0.49) SYKMETSTK17BSTK17ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK SYK 46/4885MET 599/4885STK17B 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.